NYSE$SOLV

Solventum Corporation · Q2 2024 earnings

Q2 2024 earnings · · Investor relations

Briefing

Solventum's Q2 2024 financial results were reported, with sales increasing and full-year guidance raised.

Solventum reported its Q2 2024 financial results, highlighting a slight increase in reported sales and organic sales growth. The company's GAAP EPS was $0.51, while adjusted EPS reached $1.56. Solventum generated $355 million in cash from operations and $297 million in free cash flow. The company also raised its full-year 2024 organic sales growth and adjusted EPS guidance.

  • Reported sales increased by 0.2% to $2.081 billion, with organic sales up by 1.3%.
  • GAAP Earnings Per Share (EPS) was $0.51, and adjusted EPS was $1.56.
  • Cash from operations amounted to $355 million, with a free cash flow of $297 million.
  • Full-year 2024 organic sales growth and adjusted EPS guidance were raised.

Headline financials

Total Revenue

$2.08B

Previous: $2.08B+0.2%
EPS

$0.51

Previous: $1.86-72.6%
Capital Expenditures

-$160M

Previous: $71M-325.4%
Free Cash Flow

-$71M

Previous: $295M-124.1%
Net Income

$89M

Previous: $321M-72.3%
Operating Income

$244M

Previous: $411M-40.6%
Gross Profit

$1.14B

Previous: $1.16B-2.2%
Cash & Equivalents

$897M

Previous: $39M+2200.0%
Total Assets

$14.6B

No prior period
R&D Expense

$192M

No prior period
Stock-Based Comp

$56M

Previous: $8M+600.0%

Revenue & EPS history

Solventum · Revenue · Quarterly

$2.08B

Q2 2024+0.2%vs Q2 2023
Beat estimate in 6 of 10 quarters(60%)
ActualEstimate

Revenue by segment

Solventum · $1.83B total across 3 segments · Q3 2023

  • MedSurg
    $1.18B
  • Dental Solutions
    $331M
  • Health Information Systems
    $321M

Forward guidance

Solventum is raising its full-year 2024 guidance.

Tailwinds

  • Organic sales growth of 0% to +1.0% (previously -2% to 0%)
  • Adjusted EPS of $6.30 to $6.50 (previously $6.10 to $6.40)
  • Free cash flow of $700M to $800M (no change to prior guidance)

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 12 quarterly earnings reports · overlaid with Q2 2024

Historical avgQ2 2024

+0.2%

Avg return

Earnings day

+0.1%

Avg return

5 days after

+2.1%

Avg return

30 days after

42%

5 / 12 earnings

Positive

+8.4%

Q2 2024

Best reaction

-4.7%

Q3 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.4%+8.7%+21.2%
Q4 2025-3.7%-8.5%-18.4%
Q3 2025+7.7%+11.4%+28.9%
Q2 2025+1.7%+3.4%+1.1%
Q1 2025+5.5%+6.8%+12.3%
Q4 2024-4.4%-6.7%-10.4%
Q3 2023-4.7%-6.7%-6.8%
Q3 2024-2.3%-4.6%-5.6%
Q2 2023-1.6%-1.5%+12.9%
Q2 2024+8.4%+4.2%+18.4%
Q1 2023-2.6%-3.7%-13.0%
Q1 2024-4.0%-2.0%-15.1%
Q4 2023
Q4 2022
Q3 2022
Q2 2022
Q1 2022

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro